# Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

> **NCT05554575** · PHASE1 · UNKNOWN · sponsor: **Bioceltech Therapeutics, Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- T Cell Lymphoblastic Lymphoma

## Interventions

- **BIOLOGICAL:** BT-007 CD7 CAR-T cells

## Key facts

- **NCT ID:** NCT05554575
- **Lead sponsor:** Bioceltech Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05554575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05554575, "Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05554575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*